The immunotherapies also available for advanced-stage melanoma are based on CTLA-4 and PD-1 blockers, which confer a survival benefit and more durable responses, compared to targeted therapies (Luke et al., 2017; O’Donnell et al., 2019; Yu et al., 2019). The gene discussed is PDCD1; the disease is melanoma.